Alterity Therapeutics Limited (NASDAQ:ATHE) Short Interest Up 12.6% in January

Alterity Therapeutics Limited (NASDAQ:ATHE) was the recipient of a large growth in short interest in January. As of January 15th, there was short interest totalling 167,300 shares, a growth of 12.6% from the December 31st total of 148,600 shares. Currently, 2.0% of the shares of the stock are short sold. Based on an average trading volume of 64,600 shares, the days-to-cover ratio is presently 2.6 days.

Alterity Therapeutics Stock Performance

NASDAQ:ATHE traded down $0.05 on Monday, hitting $4.75. 396,110 shares of the stock were exchanged, compared to its average volume of 1,333,451. Alterity Therapeutics has a 52 week low of $1.00 and a 52 week high of $5.87. The company’s 50-day moving average price is $2.78 and its 200 day moving average price is $1.83.

Institutional Investors Weigh In On Alterity Therapeutics

A hedge fund recently raised its stake in Alterity Therapeutics stock. HB Wealth Management LLC boosted its holdings in shares of Alterity Therapeutics Limited (NASDAQ:ATHE) by 34.1% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 31,883 shares of the company’s stock after acquiring an additional 8,100 shares during the period. HB Wealth Management LLC owned 0.44% of Alterity Therapeutics worth $110,000 as of its most recent filing with the SEC. 2.14% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ATHE. Maxim Group upped their target price on shares of Alterity Therapeutics from $8.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday. Benchmark downgraded Alterity Therapeutics from a “speculative buy” rating to a “hold” rating in a report on Monday.

Alterity Therapeutics Company Profile

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.